Morgan Stanley Reiterates Equal-Weight Rating on Abbott Laboratories

In a report published Monday, Morgan Stanley reiterated its Equal-Weight rating on Abbott Laboratories ABT. Morgan Stanley noted, “The critical debates on the new Abbott are: (i) feasibility of upper-single-digit growth, (ii) magnitude of operating leverage and visibility of double-digit earnings growth and (iii) whether a valuation inefficiency exists. We believe Abbott has set expectations at a fair level and is likely to hit targets for mid- to high-single-digit revenue and 10%+ EPS growth.” Abbott Laboratories closed on Friday at $65.53.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationAnalyst RatingsMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!